Protez Pharmaceuticals' Unattributed VC - II Round

Protez Pharmaceuticals raised a round of funding on July 21, 2005. Investors include Innovation Philadelphia.

Protez Pharmaceuticals entered a 20-site Phase II human clinical trial in 2008 with its lead compound, PZ-601, a antibiotic candidate focused on drug resistance in difficult to treat infections.…

Articles about Protez Pharmaceuticals' Unattributed VC - II Round: